Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.

Fenoldopam is a peripherally acting dopamine-receptor agonist that has vasodilator and diuretic actions. Given intravenously, it is an effective treatment for patients with severe hypertension, including those with hypertensive encephalopathy and perioperative hypertension. This review summarizes the pharmacologic characteristics of fenoldopam and its efficacy as a treatment for patients with severe hypertension.

[1]  H. Gombotz,et al.  DA1‐receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension , 1998, Acta anaesthesiologica Scandinavica.

[2]  S. Higuchi,et al.  Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  M. Lokhandwala,et al.  Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. , 1982, Journal of autonomic pharmacology.

[4]  R. Luther,et al.  The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. , 1999, Critical care medicine.

[5]  R. A. Silverman,et al.  Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans , 1991, Clinical pharmacology and therapeutics.

[6]  W. Elliott,et al.  Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. , 1990, Circulation.

[7]  D. Power,et al.  Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. , 1999, Clinical and experimental pharmacology & physiology. Supplement.

[8]  D. Bourne,et al.  The Pharmacology of Verapamil. III. Pharmacokinetics in Normal Subjects After Intravenous Drug Administration , 1981, Journal of cardiovascular pharmacology.

[9]  A. Aperia,et al.  Inhibition of proximal tubule Na(+)-K(+)-ATPase activity requires simultaneous activation of DA1 and DA2 receptors. , 1990, The American journal of physiology.

[10]  P. Mcclelland,et al.  Delayed recovery of renal function in patients with acute renal failure due to accelerated hypertension. , 1991, Postgraduate medical journal.

[11]  H. Sarau,et al.  Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. , 1982, The Journal of pharmacology and experimental therapeutics.

[12]  K. Hanaoka,et al.  Interactions between nicardipine and enflurane, isoflurane, and sevoflurane , 1997, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[13]  R. Stote,et al.  The effect of acetaminophen on the disposition of fenoldopam: Competition for sulfation , 1987, Clinical pharmacology and therapeutics.

[14]  P. Singhal,et al.  Dopamine Attenuates the Contractile Response to Angiotensin II in Isolated Rat Glomeruli and Cultured Mesangial Cells , 1986, Circulation research.

[15]  R. N. Brogden,et al.  Fenoldopam , 1997, Drugs.

[16]  S. Oparil,et al.  Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. , 2008, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[17]  B. Brenner,et al.  Quantitative importance of changes in postglomerular colloid osmotic pressure in mediating glomerulotubular balance in the rat. , 1973, The Journal of clinical investigation.

[18]  R. Ruffolo,et al.  Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058. , 1991, The Journal of pharmacology and experimental therapeutics.

[19]  D. Tempe,et al.  Control of tachycardia and hypertension following coronary artery bypass graft surgery: efficacy and haemodynamic effects of esmolol. , 1999, Indian heart journal.

[20]  L. Goldberg,et al.  The Pharmacological Basis of the Clinical Use of Dopamine , 1977, Proceedings of the Royal Society of Medicine.

[21]  P. Weidmann,et al.  Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam. , 1987, Hypertension.

[22]  G. Bakris,et al.  Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. , 1999, Kidney international.

[23]  A. Sjoerdsma,et al.  Effects of several monoamine oxidase inhibitors on the cardiovascular actions of naturally occurring amines in the dog. , 1959, The Journal of pharmacology and experimental therapeutics.

[24]  J. Pool,et al.  Sustained Hemodynamic Effects of the Selective Dopamine‐1 Agonist, Fenoldopam, during 48‐Hour Infusions in Hypertensive Patients: A Dose‐Tolerability Study , 1999, Journal of clinical pharmacology.

[25]  R. Tripathi,et al.  Effects of selective dopamine-1 receptor activation on intraocular pressure in man. , 1988, Experimental Eye Research.

[26]  B. Materson,et al.  Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital , 1999, Journal of Human Hypertension.

[27]  M. Lee,et al.  Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. , 1986, British journal of clinical pharmacology.

[28]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[29]  S H Shin,et al.  Dopamine agonists both stimulate and inhibit prolactin release in GH4ZR7 cells. , 1999, European journal of endocrinology.

[30]  F. Douglas,et al.  Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. , 1987, Circulation.

[31]  T. Dousa,et al.  ANP inhibits Na(+)-H+ antiport in proximal tubular brush border membrane: role of dopamine. , 1990, Kidney international.

[32]  R. Ruffolo,et al.  Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam. , 1990, The Journal of pharmacology and experimental therapeutics.

[33]  H. Favre,et al.  Fenoldopam Improves Renal Hemodynamics Impaired by Positive End‐Expiratory Pressure , 1993, Anesthesiology.

[34]  R. Carey,et al.  The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man. , 1988, The Journal of clinical endocrinology and metabolism.

[35]  R. Feneck,et al.  A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. , 1993, Journal of cardiothoracic and vascular anesthesia.

[36]  C. Vesey,et al.  Decay of nitroprusside. I: In vitro. , 1990, British journal of anaesthesia.

[37]  F. Dunn,et al.  Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. , 1984, Circulation.

[38]  D. Jorkasky,et al.  Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure. , 1998, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[39]  R. Branch,et al.  Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: a micropuncture study. , 1990, The Journal of pharmacology and experimental therapeutics.

[40]  J. Piltz-seymour,et al.  Effect of Intravenous Fenoldopam on Intraocular Pressure in Ocular Hypertension , 1997, Journal of clinical pharmacology.

[41]  J. Thorner,et al.  Model systems for the study of seven-transmembrane-segment receptors. , 1991, Annual review of biochemistry.

[42]  D. Taylor,et al.  Involvement of dopamine receptor subtypes in dopaminergic modulation of aldosterone secretion in rats. , 1987, Life sciences.

[43]  G. Chertow,et al.  Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. , 1996, The American journal of medicine.

[44]  R. Carey,et al.  Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[45]  W. Arendshorst,et al.  Tubuloglomerular feedback and blood flow autoregulation during DA1-induced renal vasodilation. , 1990, The American journal of physiology.

[46]  G. Dunea,et al.  Transient and sustained recovery from renal shutdown in accelerated hypertension. , 1986, The American journal of medicine.

[47]  M. Murphy,et al.  Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. , 1988, British journal of clinical pharmacology.

[48]  D. C. Dyer,et al.  The emetic effect of B-HT 920 and apomorphine in the dog: antagonism by haloperidol. , 1986, Life sciences.

[49]  D. Lampard,et al.  Local Cerebral Blood Flow and the Electrocorticogram during Sodium Nitroprusside Hypotension , 1978, Anaesthesia and intensive care.

[50]  A. Schoolwerth,et al.  Hormonal interactions with the proximal Na(+)-H+ exchanger. , 1990, The American journal of physiology.

[51]  R. Childers,et al.  Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. , 1992, Archives of internal medicine.

[52]  P. Godard,et al.  Enoximone vs nicardipine during the early postoperative course of patients undergoing cardiac surgery. A prospective study of two therapeutic strategies. , 1994, Chest.

[53]  E. Reisin,et al.  Intravenous Fenoldopam Versus Sodium Nitroprusside in Patients With Severe Hypertension , 1990, Hypertension.

[54]  D. Jorkasky,et al.  Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[55]  R. Goyal,et al.  Characterization of Dopamine Receptor Subtypes Involved in Experimentally Induced Gastric and Duodenal Ulcers in Rats , 1999, The Journal of pharmacy and pharmacology.

[56]  J. Pool,et al.  Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. , 1999, American journal of hypertension.

[57]  C. Felder,et al.  Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase. , 1990, The American journal of physiology.

[58]  M. Goldberg,et al.  Fenoldopam infusion for the treatment of postoperative hypertension. , 1993, Journal of clinical anesthesia.

[59]  R. Ruffolo,et al.  Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. , 1992, The Journal of pharmacology and experimental therapeutics.

[60]  D. Sibley,et al.  Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.

[61]  C. Pang,et al.  In vivo venodilator action of fenoldopam, a dopamine D1‐receptor agonist , 2000, British journal of pharmacology.

[62]  D. Wiest.  Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. , 1995, Clinical pharmacokinetics.

[63]  S. Apparsundaram,et al.  Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats. , 1991, Journal of Pharmacology and Experimental Therapeutics.

[64]  P. Greengard,et al.  Phosphorylated Mr 32,000 dopamine- and cAMP-regulated phosphoprotein inhibits Na+,K(+)-ATPase activity in renal tubule cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[65]  G. Chertow,et al.  "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. , 1996, Kidney international.

[66]  D. Lang,et al.  Evidence That Specific Dopamine‐1 Receptor Activation Is Involved in Dopamine‐Induced Renin Release , 1989, Hypertension.

[67]  J. Moyer.  Hydrallazine (apresoline) hydrochloride; pharmacological observations and clinical results in the therapy of hypertension. , 1953, A.M.A. archives of internal medicine.

[68]  R. Lewis,et al.  Guidelines for clinical investigator involvement in industry-sponsored clinical trials. SAEM Research Committee. , 1995, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[69]  R. Felder,et al.  The renal dopamine receptors. , 1992, Journal of the American Society of Nephrology : JASN.

[70]  K. Yamada,et al.  The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia. , 1996, The Journal of pharmacology and experimental therapeutics.

[71]  W. Reitsma,et al.  Renal and endocrine effects of fenoldopam and metoclopramide in normal man. , 1990, Nephron.

[72]  K. Sumikawa,et al.  Decrease in vecuronium infusion dose requirements by nicardipine in humans. , 1994 .

[73]  Alun D. Hughes,et al.  DEMONSTRATION OF VASCULAR DOPAMINE-RECEPTORS IN THE HUMAN FOREARM ARTERIAL CIRCULATION , 1986 .

[74]  K. S. Kim,et al.  Neuromuscular interactions between mivacurium and esmolol in rabbits , 1998, Anaesthesia.

[75]  R. Carey,et al.  Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. , 1984, The Journal of clinical investigation.

[76]  M. Goldberg.  Medical treatment of peptic ulcer disease: is it truly efficacious? , 1984, The American journal of medicine.